First day of trading in warrants of series TO1 and TO2 has been set for October 14, 2020
As previously announced, Cereno Scientific AB (”Cereno” or the ”Company”) has carried out a directed issue of shares and warrants of series TO1 and TO2 with issue funds of approximately SEK 60 million (the “Directed Issue”). In addition to the Directed Issue, the Company has simultaneously issued warrants of series TO1 and TO2 granted to (i) the Companys’s existing shareholders as compensation for the dilution caused by the Directed Issue and to (ii) Formue Nord Fokus A/S in its capacity as lender. The Company hereby announces that the first day for trading for the warrants of series TO1 and TO2 respectively has been set for October 14, 2020.
Additional terms for the warrants of series TO1 and TO2 as well as further information about the Directed Issue, the loan financing and the allotment of warrants to existing shareholders can be found in the Company’s press release as per September 30, 2020.
Warrants of series TO1 and TO2 respectively will be admitted to trading on Spotlight Stock Market. First day of trading has been set for October 14, 2020.
The instruments will be traded under the following short names and codes:
CRNO TO1 B, ISIN SE0014965687, FISN CERENOSCIE/OPT RTS 20210929 and CFI RSSXXR.
CRNO TO2 B, ISIN SE0014965695, FISN CERENOSCIE/OPT RTS 20220928 and CFI RSSXXR.
Advisers
Mangold Fondkommission AB has acted as sole bookrunner and financial adviser and MAQS Advokatbyrå has acted as legal adviser in connection with the capital raise.
For more information about Cereno:
Daniel Brodén, CFO
E-mail: info@cerenoscientific.com
Telephone: +46 768 66 77 87
www.cerenoscientific.se
About Cereno Scientific AB
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties. A clinical phase II study program for CS1 in PAH is planned to start during spring 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca's BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish stock market Spotlight, ticker: CRNO B, ISIN SE0008241558. More information on www.cerenoscientific.com.